Vanessa Kondziolka
Family · Chesterfield, MINPI 1871735563
Payments from drug & device makers
Across 337 payments — averaging $21.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$830
- GSK$733
- Takeda Pharmaceuticals U.S.A., Inc.$587
- Amgen$232
- plus $2K from 19 others
What the payments were for
- Food & beverage$7,01097%
- Education$2393%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 70 | $1,732 |
| AstraZeneca | 86 | $1,598 |
| Regeneron Healthcare Solutions, Inc. | 32 | $830 |
| GSK | 45 | $733 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $587 |
| Amgen | 13 | $232 |
| Novartis | 10 | $214 |
| Genentech USA, Inc. | 8 | $209 |
| Kaleo, Inc. | 8 | $202 |
| Boehringer Ingelheim | 8 | $149 |
| CSL Behring | 6 | $129 |
| Pfizer | 4 | $88 |
| Sanofi-aventis U.S. LLC | 1 | $72 |
| Alk-abello, Inc | 4 | $72 |
| Optinose US, Inc. | 4 | $68 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $67 |
| Teva Pharmaceuticals USA, Inc. | 3 | $66 |
| Aimmune Therapeutics, Inc. | 2 | $48 |
| Phadia US Inc. | 2 | $36 |
| Covis Pharma GmbH | 2 | $24 |
| Incyte Corporation | 1 | $24 |
| Seqirus USA Inc | 1 | $20 |
| Merck | 1 | $19 |
| Organon | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$122
How this compares
$7,250 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FasenraBenralizumab | 13 | $73,371 |
| NucalaMepolizumab | 18 | $62,452 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $49,100 |
| Spiriva RespimatTiotropium Bromide | 28 | $26,231 |
| Advair HfaFluticasone Propion/Salmeterol | 34 | $17,471 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $16,233 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $14,788 |
| Pulmicort FlexhalerBudesonide | 17 | $8,637 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $6,777 |
| Qvar RedihalerBeclomethasone Dipropionate | 14 | $6,106 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $4,058 |
| Epinephrine | 14 | $3,465 |
| Mometasone Furoate | 14 | $2,882 |
| Azelastine Hcl | 62 | $2,748 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 60 | $2,733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta | $733 | $127,78678 claims |
| AstraZenecaFasenra, Pulmicort Flexhaler, Symbicort | $1,598 | $88,78543 claims |
| Boehringer IngelheimSpiriva Respimat | $149 | $26,23128 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $66 | $6,10614 claims |
| Hikma Pharmaceuticals USAEpinephrine | $14 | $3,46514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.
Other family in Chesterfield
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.